Moderna, Inc. (MRNA) is sliding lower on Friday, last changing hands at $213.11 on the NASDAQ. That is a $23.40 decline from the prior close of $236.51 and one of the sharpest single-session drops in the stock's recent run. Even after the selloff, the shares sit only about 12.0% below their 52-week high of $242.29 and remain roughly 856% above the 52-week low of $22.28. That distance shows how much ground the stock covered before today's reversal, and how much gain is still exposed to further profit-taking.
Volume stood at roughly 11.17 million shares at the time of the quote, compared with a 90-day average of about 16.03 million. Turnover is running below its recent norm despite the size of the decline.
Why Moderna, Inc. Price is Moving Lower
The most plausible driver is profit-taking after an exceptionally large and concentrated rally, rather than any new earnings shock. On October 15, Citigroup downgraded Moderna from Neutral to Sell. The firm argued that the stock's roughly 222% recent rally had pushed valuation to unsustainable levels. That call landed on a stock that had climbed more than 600% year to date, compared with about 23% for the XBI biotech index. The advance was driven largely by enthusiasm around Moderna's personalized cancer-vaccine program. With gains of that magnitude on the books, a high-profile downgrade gave holders a clear reason to lock in profits.
The selling was concentrated in Moderna rather than spread across the group. BioNTech SE (BNTX) slipped 1.90%, and Pfizer (PFE) edged up about 0.3%. That pattern points to stock-specific valuation pressure, not a broad retreat from vaccine or mRNA names. Revolution Medicines, Inc. (RVMD) fell a steeper 5.13%. Still, the dispersion across Health Care peers suggests the downgrade and Moderna's outsized run, not sector sentiment, set the tone for today's move.
The fundamentals offer limited support for the valuation the rally produced. In the quarter reported on July 31, Moderna posted EPS of -$1.97 against a -$2.03 estimate, a $0.06 beat. Revenue was $145 million against expectations of $102.93 million. Revenue rose just 2.1% year over year, and the company still reported a $0.8 billion GAAP net loss, a -141.43% net margin, and a -28.30% return on equity. Moderna has scheduled Q3 results for November 6, 2026. That report and its pipeline updates are the next major test of whether the oncology story can justify a market value near $94 billion. Some investors appear to be reducing exposure ahead of it.
What is the Moderna, Inc. Rating - Should I Sell?
Weiss Ratings assigns MRNA a D- rating. The rating was upgraded on 3/12/2026. Current recommendation is Sell. The March upgrade moved the stock off its lowest rung, but the D- still carries a Sell recommendation. It signals that the extraordinary share-price performance this year has not offset the operating losses underneath it.
The strongest parts of the profile are the balance sheet and the return history. The Excellent rating on the Solvency Index reflects a company that built a large cash cushion during the pandemic vaccine years. That cushion allows Moderna to fund a heavy late-stage oncology and respiratory pipeline without leaning on debt. It also gives the company time to execute, which matters for a business losing roughly $0.8 billion in a single quarter. The Total Return Index is also rated Excellent, which follows directly from a stock that has run more than 600% year to date. Even after today's pullback, shareholders who held through the year have been rewarded far beyond the broader biotech index.
Where the picture deteriorates is in the operating business itself. The Very Weak rating on the Efficiency Index is backed by a -141.42% profit margin and a -28.30% ROE. Those figures show a company spending far more on research and commercialization than its shrinking respiratory vaccine franchise brings in. A trailing EPS of -$7.98 and a forward P/E of -29.62 indicate that profitability is not yet in sight. The Fair rating on the Growth Index reflects 2.11% year-over-year revenue growth, a thin top-line expansion for a company priced on future oncology approvals. The Weak Volatility Index is the cost of that setup. A stock that compounded several hundred percent on pipeline enthusiasm can surrender nearly 10% in a session on a single valuation-driven downgrade, as it did today.
Within the Health Care sector, Moderna sits alongside BioNTech SE (BNTX, D-), Natera, Inc. (NTRA, D-), and Revolution Medicines, Inc. (RVMD, D-). It trails Zoetis Inc. (ZTS, D), whose profile is modestly stronger in Weiss's framework. All of these names still carry Sell recommendations, which underscores how much risk the Weiss model sees across this corner of the market.
About Moderna, Inc.
Moderna, Inc. (MRNA) is a Health Care company built around messenger RNA technology. Its platform instructs the body's own cells to produce proteins that can prevent or treat disease. Founded in 2010 and headquartered in Cambridge, Massachusetts, the company became a global name through Spikevax, its COVID-19 vaccine. Spikevax generated the windfall revenue that still supports the balance sheet. Moderna has since broadened its commercial respiratory portfolio with mRESVIA, its vaccine for respiratory syncytial virus, and mNEXSPIKE, a next-generation COVID-19 vaccine.
The center of investor attention has shifted to oncology. Working with Merck, Moderna is developing intismeran autogene, an individualized neoantigen therapy. The treatment is designed for each patient's tumor and is given alongside Keytruda in cancers such as melanoma. This personalized cancer-vaccine program drove much of the stock's 2026 rally, and its clinical and regulatory milestones are now the main swing factor in the company's valuation. The pipeline also includes candidates in seasonal influenza, combination respiratory vaccines, latent viruses, and rare diseases.
Moderna's competitive advantage rests on the speed and flexibility of its mRNA platform. The same manufacturing and design infrastructure can be redirected quickly from one target to another. Its scale of clinical data and its partnership with Merck strengthen that position against rivals such as BioNTech and Pfizer. Still, the company faces falling demand for COVID-19 vaccines, pricing pressure in respiratory markets, and the binary nature of late-stage clinical outcomes.
Investor Outlook
Moderna, Inc. (MRNA) carries a Weiss Rating of D- (Sell), and today's downgrade-driven reversal shows how exposed a stock up more than 600% this year is to valuation pressure. Investors should watch the November 6 Q3 report for progress on narrowing losses and for updates on the personalized cancer-vaccine program that drove the rally. See full rankings of all D- rated Health Care stocks inside the Weiss Stock Screener.
--